Matinas BioPharma Holdings, Inc. (MTNB) AI Stock Analysis

Matinas BioPharma Holdings, Inc., founded in 2013 and based in Bedminster, New Jersey, is a clinical-stage biopharmaceutical company leveraging its lipid nanocrystal (LNC) platform technology. The platform enhances the delivery efficacy of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its pipeline includes lead candidate LYPDISO, an omega-3 free fatty acid composition for cardiovascular and metabolic conditions, as well as MAT2203, an oral amphotericin B formulation in Phase II trials for invasive fungal infections. Matinas is also developing MAT2501 for multidrug-resistant bacteria and collaborates with the National Institute of Allergy and Infectious Diseases and Genentech, Inc.

Revenue fluctuated across recent fiscal periods, moving from $89,812 in FY2019 to $158,333 in FY2020 and $33,000 in FY2021. In FY2022, revenue grew 9560.6% to $3.2M before declining 65.6% to $1.1M in FY2023. Gross margin reached 14.1% in FY2023, while operating margin was -2168.4%. Net income remained negative over this span, recorded at -$17.4M in FY2019, -$22.4M in FY2020, -$23.3M in FY2021, -$21.0M in FY2022, and -$22.9M in FY2023. For the trailing twelve months ended June 30, 2026, revenue was $0, with quarterly revenue growth falling 100.0% year-over-year and EPS at -$17.55.

As of June 30, 2026, Matinas BioPharma held $761,000 in cash and short-term investments against total debt of $6,000, resulting in net cash of $755,000. Total assets were $3.4M and shareholders' equity was $1.8M, yielding a debt-to-equity ratio of 0.00 and a current ratio of 0.85. Operating cash flow was -$15.3M and free cash flow was -$15.5M in FY2023. Over a five-year period through FY2025, the company's share count increased by 48.1%.

With a market capitalization of $2.3M and enterprise value of $1.8M, Matinas BioPharma trades at a price-to-sales multiple of 34.8x and an EV-to-revenue multiple of 30.9x. These levels compare to a median price-to-sales multiple of 4.1x for its US-listed Healthcare peers. The stock trades at a price-to-book ratio of 1.4x. Over the 1-year period leading to October 16, 2026, the stock declined 90.8%, trailing the S&P 500 (SPY) return of 16.8%. Over 5 years, the stock fell 99.7% while SPY gained 83.0%.

Wall Street analyst coverage consists of 2 Hold ratings, with 0 Strong Buy, 0 Buy, 0 Sell, and 0 Strong Sell ratings. The mean price target is $30.00, representing an upside of 1165.8% compared to the last close of $2.37 on October 16, 2026. For the next fiscal year, consensus estimates project $0 in revenue and an EPS of $0.00. Over the last 4 quarters, the company delivered 3 EPS beats. The next earnings date is scheduled for November 9, 2026.

This page is an AI-written research summary of Matinas BioPharma Holdings, Inc. (MTNB). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: MTNB income statement, MTNB balance sheet, MTNB key metrics, MTNB analyst forecast, MTNB chart. See the MTNB stock overview for the latest quote and news.